Cramer sees 'breakout' for this stock

That clinical trials for a cholesterol-lowering drug exceed expectations will boost the developer's stock, says CNBC's Jim Cramer.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.